CMMB Chemomab Therapeutics Ltd.
USHealthcareAs of 2026-07-09 16:00
Why CMMB matters now
Chemomab Therapeutics Ltd. (CMMB) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.83 with -7.11% on the session and $11.3M in market capitalization; recent performance reads 1-month -1.94% and YTD -7.88%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-1.8M, and EPS of $-0.22. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -119.9%.
The latest indexable market news headline is "Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript" from Seeking Alpha.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Melincoff Gwen A filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.13
P/S
0.00
EV/EBITDA
-0.43
DCF Value
$1.56
FCF Yield
-119.9%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-67.9%
ROA
-63.1%
ROIC
-74.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-1.8M | $-0.22 |
| Q4 2025 | $0.00 | $-1.9M | $-0.24 |
| FY 2025 | $0.00 | $-9.0M | $-1.42 |
| Q3 2025 | $0.00 | $-1.7M | $-0.28 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
IL
Exchange
—
Beta
0.61
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.